SUBSCRIBE
SUBSCRIBE
Ben Hargreaves

Ben Hargreaves

Freelance writer

Ben Hargreaves is a freelance science journalist based in Tosse, France. Reach him on LinkedIn.

Abstract arrow direction. Technology background. High speed. Hi-tech.
Rare diseases
As New Hereditary Angioedema Drugs Flood the Market, Will Uptake Match Innovation?
This year has seen the approval of several first-in-class therapies for HAE, but in a fragmented space, experts question whether they will be enough to net their developers a significant share of the entrenched market.
December 1, 2025
 · 
5 min read
 · 
Ben Hargreaves
Hair damaged Repair Solution concept, Nourish hair of shampoo or serum
Drug Development
From Weight Loss to Hair Loss: The Search for the Next Blockbuster
A new generation of companies is eyeing the existing, sizeable hair loss market, hoping that better formulations and new scientific targets will finally produce treatments that are safer and more effective, as well as commercially successful.
November 10, 2025
 · 
6 min read
 · 
Ben Hargreaves
Highway in Phoenix, Arizona leading toward downtown at sunset
Cell and Gene Therapy
Meeting on the Mesa Arrives Amid Mixed Signals for Cell and Gene Therapy
As industry leaders gather at the annual event in Phoenix, the cell and gene therapy space remains in a state of flux, with M&A activity and regulatory support signaling momentum while commercialization challenges continue to hinder broader investor interest.
October 6, 2025
 · 
5 min read
 · 
Ben Hargreaves
Multiple sclerosis damaged myelin or MS autoimmune disease with healthy nerve with exposed fibre with scarrred cell sheath loss as a 3D illustration.
Multiple sclerosis
Beyond BTK Inhibitors: Next Gen MS Treatments Could Transcend Symptom Management
While Bruton’s tyrosine kinase inhibitors are often hailed as the next big breakthrough in multiple sclerosis, Immunic Therapeutics and others are leveraging neuroprotective targets and remyelination to keep the disease at bay.
October 6, 2025
 · 
5 min read
 · 
Ben Hargreaves
New York, United States - June 18, 2016: New York Stock Exchange with American flags and Wall street sign
FDA
Wall Street the Main Beneficiary of FDA’s Real-Time CRL Disclosures
By publishing complete response letters as soon as they are issued to drug sponsors, the FDA is expanding transparency in a way that, while positioned as a public health measure, also grants investors greater visibility into regulatory decisions. Experts question whether this is the agency’s proper remit.
September 29, 2025
 · 
6 min read
 · 
Ben Hargreaves
There is no place for the red man in the group. Social isolation. Exclusion, discrimination.
FDA
FDA Expert Panels Lack Balance in Pursuit of ‘Gold Standard Science’
New FDA expert panels, such as recent meetings on SSRI use during pregnancy and on hormone replacement therapy during menopause, are drawing criticism for being one-sided. One leader says such panels are designed to reach a specific conclusion.
September 8, 2025
 · 
6 min read
 · 
Ben Hargreaves
Human brain with abstract visualization of neuron activity
Brain Cancer
Glioblastoma Funding Rises as Nonprofits Drive Interest and Pharma Returns to the Table
After decades of limited progress—owing to the difficulty of treating the disease and resultant market risk—glioblastoma research is entering a new phase spurred by smarter trials, targeted funding and renewed interest from companies like Merck and Jazz Pharmaceuticals.
August 4, 2025
 · 
6 min read
 · 
Ben Hargreaves
Legal and law concept illustration stock illustration
Policy
Post-Chevron Legal Battles: Three Key Cases to Watch
The overturning of the FDA’s lab-developed tests rule is just the tip of the iceberg. With the loss of Chevron deference, power has shifted from federal agencies to the courts, with potential implications for everything from the FDA shortage list to CMS drug price negotiations.
June 2, 2025
 · 
7 min read
 · 
Ben Hargreaves
Coronavirus on stock market crisis business motion Financial Stock market crisis falling down in Wuhan Covid-19. Coronavirus financial outbreak losses, down Graph in front of Coronavirus Concept
COVID-19
4 Biotechs Caught Up in Uncertain COVID-19 Vaccine Landscape
As the World Health Organization initiates a new agreement for coordinating global responses to future pandemics, the future of vaccine development in the U.S. faces growing challenges, including waning funding and regulatory changes, that threaten next-gen COVID-19 vaccine candidates and pandemic preparedness more broadly.
May 27, 2025
 · 
7 min read
 · 
Ben Hargreaves
Human liver protection. Wireframe low poly style. Concept for medical, pharmacology, treatment of the hepatitis. Abstract modern 3d vector illustration on dark blue background.
MASH
7 Late-Stage MASH Candidates That Could Reshape the Market
Akero Therapeutics, 89bio, Boston Pharmaceuticals and more are working to bring novel treatment options for metabolic dysfunction-associated steatohepatitis to a market that could reach $16 billion by 2033.
April 7, 2025
 · 
6 min read
 · 
Ben Hargreaves
Contemporary art collage. Person climbs a pile of colorful capsules, symbolizing struggle and progress in surreal pharmaceutical world. Flag marks goal at top. stock photo
Manufacturing
GLP-1 Injectables Will Soon Be Joined by Orals. Is the Industry Ready to Scale?
With crucial lessons learned from the manufacturing shortages of injectable GLP-1s, experts say securing adequate supply of the upcoming oral options will be the sector’s next great challenge.
March 26, 2025
 · 
6 min read
 · 
Ben Hargreaves
Illustration silhouette people walking toward the destination of light with white line on yellow and blue empty background.
GLP-1
GLP-1 Drug Boom Recalls the Rise of PD-1 Checkpoint Inhibitors
The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences suggest history may not repeat itself.
March 19, 2025
 · 
8 min read
 · 
Ben Hargreaves
Medical doctor challenge concept and medicine challenges idea as a physician or pharmacist standing in a desert with medication symbols as a healthcare symbol with 3D illustration elements.
Drug Delivery
Explainer: The Thriving Shadow Market of GLP-1s for Weight Loss
Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The situation is causing the FDA regulatory headaches and, more seriously, posing potential risks to the public.
February 11, 2025
 · 
5 min read
 · 
Ben Hargreaves
Pictured: FDA headquarters with money and pill bottles
FDA
What Trump’s Second Term Could Mean for PDUFA’s Future
Robert F. Kennedy, Jr.—Trump’s pick for HHS secretary who endured confirmation hearings last week—has repeatedly criticized industry ties to the FDA, particularly financial links between the two, which could indicate trouble for the user-fee model.
February 3, 2025
 · 
4 min read
 · 
Ben Hargreaves
Financier with a stack of coins in his hands. Art collage.
Venture capitalists
2024’s Top 7 VC Raises in Biotech
BioSpace recaps 2024’s top venture capital rounds in biopharma, from Xaira Therapeutics’ blockbuster $1B raise to back-to-back series from obesity-focused Metsera that totaled more than $500M in a space that has garnered more than a fivefold increase in VC dollars this year.
January 15, 2025
 · 
7 min read
 · 
Ben Hargreaves
Load More